AVR trades 70.3% below Wall Street's consensus target of $16.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AVR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Anteris Technologies Global Corp. (AVR) has a Wall Street consensus price target of $16.50, based on estimates from 2 covering analysts. With the stock currently trading at $9.69, this represents a potential upside of +70.3%. The company has a market capitalization of $356M.
Analyst price targets range from a low of $15.00 to a high of $18.00, representing a 18% spread in expectations. The median target of $16.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AVR trades at a trailing P/E of -2.4x. Analysts expect EPS to grow +73.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
TMCITreace Medical Concepts, Inc. | $289M | $4.46 | $3.00 | -32.7% | Hold | — | 9 |
ATRCAtriCure, Inc. | $1.5B | $30.18 | $51.33 | +70.1% | Buy | 845.4x | 19 |
EWEdwards Lifesciences Corporation | $52.3B | $90.78 | $96.55 | +6.4% | Buy | 30.1x | 48 |
XTNTXtant Medical Holdings, Inc. | $59M | $0.42 | — | — | — | — | — |
AORTArtivion, Inc. | $1.1B | $23.61 | $40.50 | +71.5% | Buy | 248.5x | 12 |
MDTMedtronic plc | $104.0B | $80.98 | $95.80 | +18.3% | Buy | 13.6x | 51 |
ABTAbbott Laboratories | $163.4B | $93.82 | $126.00 | +34.3% | Buy | 17.1x | 41 |
BSXBoston Scientific Corporation | $65.7B | $44.23 | $82.40 | +86.3% | Buy | 13.1x | 44 |
SYKStryker Corporation | $127.4B | $332.31 | $387.46 | +16.6% | Buy | 22.2x | 51 |
Quick answers to the most common questions about buying AVR stock.
The consensus Wall Street price target for AVR is $16.5, representing 70.3% upside from the current price of $9.69. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
AVR has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $16.5 implies 70.3% upside from current levels.
AVR's current price is $9.69 with a consensus target of $16.5 (70.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for AVR, while the most conservative target is $15. The consensus of $16.5 represents the median expectation. These targets typically reflect 12-month expectations.
AVR is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AVR stock forecast based on 2 Wall Street analysts shows a consensus price target of $16.5, with estimates ranging from $15 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on AVR, with a "Buy" consensus rating and $16.5 price target (70.3% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AVR analyst price targets range from $15 to $18, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.